Summit Global Investments’s Emergent Biosolutions EBS Stock Holding History

Summit Global Investments’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,964	Closed	-$740K	–	579
2021 Q1	$740K	Buy	7,964 +664	+9%	+$68K	0.05%	248
2020 Q4	$654K	Buy	7,300 +66	+0.9%	+$6.06K	0.07%	177
2020 Q3	$747K	Sell	7,234 -7,761	-52%	-$837K	0.08%	160
2020 Q2	$1.19M	Sell	14,995 -200	-1%	-$14.9K	0.14%	109
2020 Q1	$879K	Sell	15,195 -3,100	-17%	-$179K	0.13%	95
2019 Q4	$987K	Buy	18,295 +4,275	+30%	+$232K	0.11%	123
2019 Q3	$733K	Buy	+14,020	New	+$653K	0.09%	231
2018 Q4	–	Sell	-12,800	Closed	-$843K	–	264
2018 Q3	$843K	Hold	12,800	–	–	0.11%	152
2018 Q2	$646K	Buy	12,800 +1,100	+9%	+$57.3K	0.1%	207
2018 Q1	$616K	Buy	+11,700	New	+$583K	0.1%	132

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Global Investments's EBS Position: Q2 2021 in Review

Summit Global Investments sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 7,964 shares — an estimated $740K sold.

Summit Global Investments first reported a position in EBS in Q1 2018 and held it in 10 quarters. The position peaked at $1.19M in Q2 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Summit Global Investments reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Summit Global Investments sold 7,964 Emergent Biosolutions shares in Q2 2021, an estimated $740K.
Summit Global Investments first reported a position in Emergent Biosolutions in Q1 2018 and held it in 10 quarters.
Summit Global Investments's Emergent Biosolutions position peaked at $1.19M in Q2 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Summit Global Investments's 13F filing for Q2 2021, filed 28 Jan 2022.